PF-AtlasClinical Trials › NCT02265874

Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study

Habitrol · Phase 1

Registry ID
NCT02265874
Phase
Phase 1
Status
Completed
Drug / intervention
Habitrol
Sponsor
Ohio State University
Start
2015-10-21
Enrollment
50
Locations
1

About this trial

The purpose of this study is to determine if nicotine treatment is beneficial for the treatment of sarcoidosis. Sarcoidosis is a disease of unknown cause that leads to inflammation. This disease affects your body's organs.

View NCT02265874 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT02265874 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.